Jonathan M Hazlehurst
Overview
Explore the profile of Jonathan M Hazlehurst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elhariry M, Iyer P, Isack N, Sousa B, Singh P, Abbott S, et al.
Clin Obes
. 2025 Jan;
e12731.
PMID: 39828897
Specialist weight management services including bariatric surgery are commissioned within regions of England called Integrated Care Systems (ICSs) with eligibility and treatment guidelines determined as part of the National Institute...
2.
Flint S, Brown A, Vazquez-Velazquez V, Hazlehurst J
Lancet Diabetes Endocrinol
. 2024 Nov;
12(12):878-879.
PMID: 39608962
No abstract available.
3.
4.
Knowles G, Warmington E, Shepherd L, Hazlehurst J, De Bray A, Gleeson H, et al.
Endocr Connect
. 2023 May;
12(8).
PMID: 37253239
Objective: Patients with primary adrenal insufficiency (PAI) are thought to be particularly vulnerable to coronavirus disease 2019 (COVID-19); however, little is known about its true impact on this group. We...
5.
Phillips K, Hazlehurst J, Sheppard C, Bellary S, Hanif W, Karamat M, et al.
Diabet Med
. 2023 May;
41(1):e15153.
PMID: 37223892
Aims: To determine differences in the management of diabetic kidney disease (DKD) relevant to patient sex, ethnicity and socio-economic group in UK primary care. Methods: A cross-sectional analysis as of...
6.
Gardner M, Wang J, Hazlehurst J, Sainsbury C, Blissett J, Nirantharakumar K, et al.
Diabet Med
. 2022 Oct;
40(3):e14996.
PMID: 36308066
Aims: People with pre-diabetes are at high risk of progressing to type 2 diabetes. This progression is not well characterised by ethnicity, deprivation and age, which we describe in a...
7.
Shepherd L, Schmidtke K, Hazlehurst J, Melson E, Dretzke J, Hawks N, et al.
Eur J Endocrinol
. 2022 May;
187(1):S1-S20.
PMID: 35536876
Objective: The incidence of adrenal crisis (AC) remains high, particularly for people with primary adrenal insufficiency, despite the introduction of behavioural interventions. The present study aimed to identify and evaluate...
8.
Hazlehurst J, Singh P, Bhogal G, Broughton S, Tahrani A
Clin Endocrinol (Oxf)
. 2022 Mar;
97(2):208-216.
PMID: 35319122
Obesity exacerbates the phenotype of polycystic ovarian syndrome (PCOS) including infertility as well as reducing the efficacy and access to fertility treatments. Weight management is, therefore, a key component of...
9.
Gathercole L, Nikolaou N, Harris S, Arvaniti A, Poolman T, Hazlehurst J, et al.
J Endocrinol
. 2022 Mar;
253(3):97-113.
PMID: 35318963
Steroid 5β-reductase (AKR1D1) plays important role in hepatic bile acid synthesis and glucocorticoid clearance. Bile acids and glucocorticoids are potent metabolic regulators, but whether AKR1D1 controls metabolic phenotype in vivo...
10.
Hazlehurst J, Lim T, Charlton C, Miller J, Gathercole L, Cornfield T, et al.
Metabol Open
. 2022 Mar;
14:100177.
PMID: 35313531
Background And Aims: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver condition. It is tightly associated with an adverse metabolic phenotype (including obesity and type 2 diabetes)...